Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

VLTR-559 was well tolerated at target clinical dose with a safety profile similar to approved short-acting anti-VEGF therapies for wet AMD Data featured in an oral presentation at the at the ...

Ivonescimab’s progression-free survival data bode well for an upcoming overall survival readout, according to Truist analysts ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced ...

Simultaneous PD-1/VEGF/CTLA-4 blockade aims to compress multi-drug regimens into a single infusion, raising questions about ...

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus ...

On cycle 1 day 8, CS2009 induced notable, dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and ...

Ivonescimab combined with chemotherapy significantly improved progression-free survival (PFS) compared with Tevimbra ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...